Literature DB >> 8617155

Middle and long latency somatosensory evoked potentials after painful laser stimulation in patients with fibromyalgia syndrome.

J Lorenz1, K Grasedyck, B Bromm.   

Abstract

Ten female patients with fibromyalgia syndrome (FS) were investigated with laser evoked potentials (LEPs) after hand stimulations and compared with 10 female pain-free and age-matched control patients. FS patients exhibited significantly lower heat pain thresholds than controls (P < 0.05) and had higher amplitudes of LEP components N170 (P < 0.01) and P390 (P < 0.05) in response to intensities of 20 W (beam diameter 5 mm, duration 20 msec, wavelength 10.6 microns). N170 additionally appeared with a broader distribution over bilateral central, vertex and fronto-central leads which contrasted to the control group and studies in healthy subjects where N170 was much more restricted to central and midtemporal positions contralateral to the stimulated hand. Auditory stimuli interspersed between laser impulses that served to announce subjects to rate the perceived pain elicited auditory evoked potentials that were not different between groups indicating no differences of general vigilance level to account for observed LEP effects. P390 amplitude enhancement might indicate greater attention and cognitive processing of nociceptive stimuli in FS subjects. Effects upon N170 rather point to exogenous factors like peripheral and spinal sensitization or reduced cortical or subcortical inhibition of nociception.

Entities:  

Mesh:

Year:  1996        PMID: 8617155     DOI: 10.1016/0013-4694(95)00259-6

Source DB:  PubMed          Journal:  Electroencephalogr Clin Neurophysiol        ISSN: 0013-4694


  33 in total

1.  Update on laser-evoked potential findings in fibromyalgia patients in light of clinical and skin biopsy features.

Authors:  Marina de Tommaso; Maria Nolano; Florenzo Iannone; Eleonora Vecchio; Katia Ricci; Marta Lorenzo; Marianna Delussi; Francesco Girolamo; Vito Lavolpe; Vincenzo Provitera; Annamaria Stancanelli; Giovanni Lapadula; Paolo Livrea
Journal:  J Neurol       Date:  2013-12-24       Impact factor: 4.849

Review 2.  The role of sleep in pain and fibromyalgia.

Authors:  Ernest H S Choy
Journal:  Nat Rev Rheumatol       Date:  2015-04-28       Impact factor: 20.543

3.  Treatment-related changes in brain activation in patients with fibromyalgia syndrome.

Authors:  Martin Diers; Pinar Yilmaz; Mariela Rance; Kati Thieme; Richard H Gracely; Claudia Rolko; Marcus T Schley; Ulrike Kiessling; Haili Wang; Herta Flor
Journal:  Exp Brain Res       Date:  2012-03-17       Impact factor: 1.972

Review 4.  Fibromyalgia Pathogenesis and Treatment Options Update.

Authors:  Steven Chinn; William Caldwell; Karina Gritsenko
Journal:  Curr Pain Headache Rep       Date:  2016-04

5.  Nociceptive pathway function is normal in cervical dystonia: a study using laser-evoked potentials.

Authors:  Michele Tinazzi; Massimiliano Valeriani; Giovanna Squintani; Federica Corrà; Serena Recchia; Giovanni Defazio; Alfredo Berardelli
Journal:  J Neurol       Date:  2012-02-18       Impact factor: 4.849

Review 6.  Role of functional brain imaging in understanding rheumatic pain.

Authors:  Anthony K P Jones; Nathan T M Huneke; Donna M Lloyd; Chris A Brown; Alison Watson
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

Review 7.  [Chronic pain : Perception, reward and neural processing].

Authors:  S Becker; M Diers
Journal:  Schmerz       Date:  2016-10       Impact factor: 1.107

8.  Nerve conduction tests in patients with fibromyalgia: comparison with normal controls.

Authors:  Murat Ersoz
Journal:  Rheumatol Int       Date:  2003-01-04       Impact factor: 2.631

Review 9.  Fibromyalgia: an update and immunological aspects.

Authors:  Eduardo S Paiva; Evelin Diana Goldenberg Mariano da Costa; Morton Scheinberg
Journal:  Curr Pain Headache Rep       Date:  2008-10

Review 10.  [Neuroendocrine changes and maladaptations in fibromyalgia. Etiopathogenetic findings].

Authors:  K Thieme
Journal:  Orthopade       Date:  2004-05       Impact factor: 1.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.